ABH Healthcare IPO Financials, Risk Factors, Peers & Objects of Issue

An investor-focused breakdown of the ABH Healthcare IPO offer document: restated financial performance, key ratios, valuation across the price band, competitive strengths, risk factors, listed peers, objects of the issue and the business model, all drawn from the company's RHP disclosures.

Back to the ABH Healthcare IPO report → (allotment, subscription, GMP)

ABH Healthcare IPO Financial Performance (Restated)

On a restated consolidated basis, the company revenue increased by 7% and profit after tax (PAT) rose by 5% between the financial year ending with March 31, 2026, a useful one-line read on operating momentum heading into the listing.

Here is how the books have moved over the last three financial years:

All figures in ₹ Crore unless stated otherwise. Source: restated financials disclosed in the offer documents.

Profits have scaled from ₹1.66 Cr to ₹5.64 Cr over two years; the borrowings-to-net-worth ratio has eased to about 2.65. For investors, the trend matters more than any single year, steady compounding with contained leverage is what institutional bidders typically reward, while a late spike in borrowings deserves scrutiny against the stated objects of the issue.

ABH Healthcare IPO Key Performance Indicators (KPI)

Reading these numbers. RoE and RoCE measure how efficiently the business turns shareholder capital into profit; anything in double digits is respectable, mid-twenties plus is strong. A debt-to-equity ratio well below 1 signals a balance sheet that does not depend on lenders. NAV per share anchors the book value of your bid, while price-to-book tells you how many rupees the issue is charging for each rupee of that book, compare it with listed peers in the same sector before deciding whether the premium is justified.

ABH Healthcare IPO Valuation, Pre IPO vs Post IPO

The issue price converts into a different earnings multiple once the fresh shares hit the books. Here is the dilution-adjusted picture:

Pre-IPO figures are computed on the pre-issue share count; post-IPO figures assume full subscription at the upper band.

ABH Healthcare IPO Competitive Strengths (as disclosed in the RHP)

ABH Healthcare IPO Risk Factors (per RHP)

It is essential to read the complete risk factors in the offer document before investing; this list summarises the key disclosures only.

ABH Healthcare IPO Business Model

• Company is ABH Healthcare Private Limited, operating in the healthcare/hospital services space.
• Undertaking of Anil Baghi Hospital was acquired via a Business Transfer Agreement dated March 16, 2022.
• Linked to promoter-affiliated entities Five Creeks Healthcare LLP and ABH Clinics LLP through supplementary LLP agreements dated November 20, 2024.
• Business is led by doctor-promoters: Dr. Kamal Baghi (Chairman & Whole-Time Director), Dr. Saurabh Baghi (Managing Director) and Dr. Vaishali Saini (Non-Executive Director).
• Proposing an equity share issue with listing on NSE Emerge platform, per NSE approval letter dated December 1, 2025.
• Restated consolidated financials for Fiscal 2024, 2025 and 2026 reported by statutory and peer review auditor M/s G.D. Singhal & Associates.
• No manufacturing activity indicated; revenue model, customer segments, capacity/scale numbers and location details are not disclosed in this excerpt.

ABH Healthcare IPO Industry Snapshot

• Government of India's consolidated FDI Policy Circular of 2020 ('FDI Policy 2020'), issued by DIPP and effective October 15, 2020, governs foreign direct investment across sectors including healthcare.
• RBI Master Circular on Foreign Investment in India dated July 01, 2015 (as updated) and Master Direction – Foreign Investment in India (updated up to March 08, 2019) govern fresh issue of shares to eligible non-resident investors.
• Under FDI Policy 2020, foreign investment is subject to a composite cap including all types of foreign investments (FDI, FPI, NRI/OCI, LLPs, FVCI, Investment Vehicles, DRs) under Foreign Exchange Management (Non-debt Instruments) Rules, 2019.
• Portfolio Investment Scheme (PIS): each FPI/investor group may hold up to 10% of paid-up equity capital (fully diluted) and all FPIs together up to 24%, raisable to the sectoral/statutory cap via Board and special shareholder resolutions.
• NRI/OCI holdings on repatriation basis are capped at 5% individually and 10% in aggregate of paid-up equity capital (fully diluted), raisable to 24% by special resolution; on non-repatriation basis such investments are deemed domestic at par with resident investors.
• No market size figures, growth rates (CAGR), or demand drivers are stated in this excerpt; the disclosed industry-relevant content is limited to FDI/FPI/NRI regulatory policy applicable to the issuing company.

ABH Healthcare IPO Listed Peers (per RHP)

ABH Healthcare valuation versus listed peers in the same industry, from the RHP peer set. The highlighted This IPO column shows how the issue compares on P/E and return on net worth; green marks a cheaper multiple or a stronger ROE relative to the peer median.

Issuer: ABH Healthcare Limited | Consolidated | CMP: [●] | Revenue from Operations: 5,250.69 lakhs | Basic EPS: 7.05 | Diluted EPS: 7.05 | P/E: [●] | PAT margin: 10.74% | RONW: 34.26% | NAV: 21.58 | Face Value: 10.00 | Market cap to Revenue: [●]

ABH Healthcare IPO Objects of the Issue

ABH Healthcare IPO Litigation

• Direct tax - TDS demand trace
• Direct tax - TDS demand trace

View the complete ABH Healthcare IPO report: allotment status, subscription, GMP & review →

Last updated: 02 Sep 2026, 22:25 IST